Demmel V, et al. - In this 16-week, double-blind, single-center thorough QT study, the researchers examined the potential of semaglutide, at steady-state therapeutic and supratherapeutic doses, to prolong the QT or corrected QT (QTc) interval in healthy subjects. In a parallel design, one hundred sixty-eight healthy subjects were randomized to the treatment or placebo arms, of whom one hundred sixty-six were treated with subcutaneous semaglutide or placebo. No concern was raised with regard to ventricular arrhythmias. In healthy subjects, semaglutide treatment did not prolong the cardiac repolarization duration.